SCHEMBL394387

SCHEMBL394387

Nc1ccc(C(=O)OOCC(O)CO)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 4/20 0.48
ADRB1 P08588 4/20 0.48
ADRB3 P13945 4/20 0.48
LMNA P02545 3/20 0.45
CYP1A2 P05177 3/20 0.45
CYP3A4 P08684 3/20 0.45
MAOA P21397 2/20 0.45
TSHR P16473 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
PDE4D Q08499 1/20 0.41
PHLPP2 Q6ZVD8 1/20 0.40
SCN1A P35498 2/20 0.39
SCN2A Q99250 2/20 0.39
SCN3A Q9NY46 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 1/20 0.39
CYP2D6 P10635 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lisadimate SCHEMBL62520 0.83 ADRB2 (0.66) ADRB2ADRB1ADRB3LMNACYP1A2
SCHEMBL27761466 0.83 LMNA (0.53) ADRB2ADRB1ADRB3LMNACYP1A2
Lisadimate SCHEMBL7263680 0.77 LMNA (0.71) ADRB2ADRB1ADRB3LMNACYP1A2
Lisadimate SCHEMBL28150985 0.75 ALDH1A1 (0.58) ADRB2ADRB1ADRB3LMNACYP1A2
SCHEMBL6228872 0.74 LMNA (0.59) ADRB2ADRB1ADRB3LMNACYP1A2
SCHEMBL4983780 0.73 ADRB2 (0.55) ADRB2ADRB1ADRB3ALDH1A1MAPT
Aminobenzoic Acid SCHEMBL269053 0.72 TSHR (0.48) ADRB2ADRB1ADRB3LMNACYP1A2
SCHEMBL5898880 0.71 NPC1 (0.61) ADRB2ADRB1ADRB3LMNACYP1A2
SCHEMBL19148222 0.71 ADRB2 (0.55) ADRB2ADRB1ADRB3LMNACYP1A2
SCHEMBL269052 0.70 LMNA (0.52) ADRB2ADRB1ADRB3LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 493 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190099342-A1 COOLING PRODUCT SYMRISE AG (DE) 2019-04-04 US claimed
WO-2007110415-A2 USE OF DIACETYL TRIMERS AND COSMETIC OR THERAPEUTIC FORMULATIONS CONTAINING THESE COMPOUNDS SYMRISE GMBH & CO. KG (DE) 2007-10-04 WO claimed
US-6814959-B1 SOLID AGENTS, COMPRISING POLYMORPHIC LIPID PARTICLES, WITH UV RADIATION-ABSORBING AND/OR REFLECTING ACTION FOR APPLICATION ON THE SKIN, MUCOUS MEMBRANES, SCALP AND HAIR FOR PROTECTION AGAINST HEALTH-DAMAGING UV RADIATION PHARMASOL GMBH (DE) 2004-11-09 US claimed
US-20240237643-A1 COMPOSITIONS WITH VIRUCIDAL AND/OR ANTIVIRAL ACTIVITY SYMRISE AG (DE) 2024-07-18 US disclosed
US-20240216248-A1 MICROBIAL GLYCOLIPIDS ANALYTICON DISCOVERY GMBH (DE) 2024-07-04 US disclosed
US-12023396-B2 Flavour and fragrance compositions comprising acetophenone derivatives SYMRISE AG (DE) 2024-07-02 US disclosed
WO-2024135300-A1 COSMETIC COMPOSITION, COSMETIC COMPOSITION FOR SUPPRESSING DISCOLORATION, AND DISCOLORATION SUPPRESSANT 株式会社資生堂 2024-06-27 WO disclosed
US-12016944-B2 Mixtures comprising a protein extract for the treatment of human skin and/or hair SYMRISE AG (DE) 2024-06-25 US disclosed
EP-4373462-A1 COMPOSITIONS OF DICAFFEOYLQUINIC ACIDS WITH TOCOPHEROL Symrise AG (DE) 2024-05-29 EP disclosed
US-20240122816-A1 ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN SYMRISE AG (DE) 2024-04-18 US disclosed
US-20240122834-A1 MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION SYMRISE AG (DE) 2024-04-18 US disclosed
US-20070059331-A1 SYNERGISTIC MIXTURES OF C6- TO C12-ALKANEDIOLS AND TROPOLONE (DERIVATIVES) SYMRISE GMBH & CO. KG (DE) 2007-03-15 US disclosed
EP-1761271-A1 BLACKBERRY EXTRACT Symrise GmbH & Co. KG (DE) 2007-03-14 EP disclosed
US-20070054967-A1 SYNERGISTIC MIXTURES OF AROMATIC ALCOHOLS AND DERIVATIVES THEREOF AND TROPOLONE (DERIVATIVES) SYMRISE GMBH & CO. KG (DE) 2007-03-08 US disclosed
WO-2007007863-A1 PERCUTANEOUSLY ABSORPTIVE OPHTHALMIC PREPARATION COMPRISING OLOPATADINE SENJU PHARMACEUTICAL CO., LTD. (JP) 2007-01-18 WO disclosed
WO-2007007851-A1 PERCUTANEOUSLY ABSORPTIVE OPHTHALMIC PREPARATION COMPRISING EPINASTINE SENJU PHARMACEUTICAL CO., LTD. (JP) 2007-01-18 WO disclosed
WO-2006045760-A1 USE OF GLYCOSYLATED FLAVANONES FOR THE BROWNING OF SKIN OR HAIR SYMRISE GMBH & CO. KG (DE) 2006-05-04 WO disclosed
WO-2006040349-A1 PROCESS FOR STRENGTHENING THE BARRIER FUNCTION OF UNDAMAGED SKIN SYMRISE GMBH & CO. KG (DE) 2006-04-20 WO disclosed
WO-2005123101-A1 BLACKBERRY EXTRACT SYMRISE GMBH & CO. KG (DE) 2005-12-29 WO disclosed
US-5833961-A CROSSLINKED POLYESTERS AND TWO ORGANIC ACTIVE SUNSCREEN AGENTS; SYNERGISTIC INCREASE IN SOLUBILITY; NON-IRRITATING; WATER REPELLENCY INOLEX INVESTMENT CORPORATION (US) 1998-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190099342-A1 COOLING PRODUCT TRPA1, TRPV2, NISCH ADRB2 1108/4885ADRB1 2135/4885ADRB3 2291/4885
US-12023396-B2 Flavour and fragrance compositions comprising acetophenone derivatives FAAH2, ADH5, NISCH ADRB2 1716/4885ADRB1 1388/4885ADRB3 2021/4885
US-20240122834-A1 MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION MC1R, OR51E2, TYR ADRB2 73/4885ADRB1 123/4885ADRB3 35/4885
US-20240216248-A1 MICROBIAL GLYCOLIPIDS UGCG, SGMS1, GPR119 ADRB2 2082/4885ADRB1 2031/4885ADRB3 2581/4885
US-20240122816-A1 ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN CUTA, POLR1C, SLC16A7 ADRB2 4699/4885ADRB1 4825/4885ADRB3 4432/4885
US-20240237643-A1 COMPOSITIONS WITH VIRUCIDAL AND/OR ANTIVIRAL ACTIVITY ZC3HAV1, SAMHD1, ZC3HAV1L ADRB2 2439/4885ADRB1 1486/4885ADRB3 2003/4885
US-20070054967-A1 SYNERGISTIC MIXTURES OF AROMATIC ALCOHOLS AND DERIVATIVES THEREOF AND TROPOLONE (DERIVATIVES) NR1H3, NR1H2, CBR3 ADRB2 50/4885ADRB1 42/4885ADRB3 32/4885
US-20070059331-A1 SYNERGISTIC MIXTURES OF C6- TO C12-ALKANEDIOLS AND TROPOLONE (DERIVATIVES) CBR3, CBR1, CYP3A7 ADRB2 69/4885ADRB1 57/4885ADRB3 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.